Charles Bonnet Syndrome: Successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors

被引:30
|
作者
Lang, Undine E.
Stogowski, Dariusz
Schuze, Doreen
Domula, Markus
Schmidt, Eckart
Gallinat, Jueergen
Tugtekin, Sems Malte
Felber, Werner
机构
[1] Univ Dresden, Dept Psychiat, D-01099 Dresden, Germany
[2] Univ Dresden, Dept Ophthalmol, Dresden, Germany
[3] Heart Ctr Dresden, Dept Cardiac Surg, Dresden, Germany
关键词
serotonin; Charles Bonnet Syndrome; CBS; hallucinations; epileptic; SSRI; venlafaxine; escitalopram;
D O I
10.1177/0269881106075275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Visual hallucinations are a common and often distressing consequence of vision toss, particularly in age-related macular degeneration. Charles Bonnet Syndrome (CBS) is defined by the triad of complex visual hallucinations, ocular pathology causing visual deterioration and preserved cognitive status. So far, although this condition is frequent, no established treatment for CBS has been stated. We report here the case of a 78-year-old woman, who came in our hospital because of a 4-week tong mild depressive symptomatology. For 1 year she experienced daily sudden, unexpected, vivid and elaborate hallucinations. Insight was completely present, so the patient stated that the hallucinations were unreal and that the faces, geometrical figures and animals she saw every day were possibly due to her vision loss. The Mini Mental State Examination, digit span and verbal fluency were administered and no cognitive impairment was reported. The visual acuity was hand motion. After 4 days of treatment with venlafaxine the hallucinations completely disappeared. This is the first case to show that selective serotonin (and noradrenalin) reuptake inhibitors may be an effective and well-tolerated treatment for visual hallucinations associated with vision Loss, and it adds to evidence implicating serotonergic pathways in the pathogenesis of visual hallucinations.
引用
收藏
页码:553 / 555
页数:3
相关论文
共 50 条
  • [1] Visual hallucinations and the Charles Bonnet syndrome
    Ffytche D.H.
    Current Psychiatry Reports, 2005, 7 (3) : 168 - 179
  • [2] Commentary on Visual Hallucinations and Charles Bonnet Syndrome
    Benaur, Marina
    Kahn, David
    JOURNAL OF PSYCHIATRIC PRACTICE, 2011, 17 (02) : 142 - 144
  • [3] Nonpsychotic Hallucinations and Impaired Vision: The Charles Bonnet Syndrome
    Somoza-Cano, Francisco J.
    Abuyakoub, Ahmed
    Hammad, Faris
    Jaber, Jasmin
    Al Armashi, Abdul Rahman
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [4] Charles Bonnet Syndrome as Another Cause of Visual Hallucinations
    Voit, MaryKate
    Jerusik, Brian
    Chu, Justin
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [5] Yi-Gan San for Treatment of Charles Bonnet Syndrome (Visual Hallucination Due to Vision Loss): An Open-Label Study
    Miyaoka, Tsuyoshi
    Furuya, Motohide
    Kristian, Liaury
    Wake, Rei
    Kawakami, Kazunori
    Nagahama, Michiharu
    Kawano, Kiminori
    Ieda, Masa
    Tsuchie, Keiko
    Horiguchi, Jun
    CLINICAL NEUROPHARMACOLOGY, 2011, 34 (01) : 24 - 27
  • [6] Visual Hallucinations (Charles Bonnet Syndrome) Associated with Neurosarcoidosis
    Zhang, Jason
    Waisbren, Emily
    Hashemi, Nafiseh
    Lee, Andrew G.
    MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY, 2013, 20 (04) : 369 - 371
  • [7] Eye-related visual hallucinations: Consider 'Charles Bonnet syndrome'
    Cinar, Nilgun
    Sahin, Sevki
    Karsidag, Sibel
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2011, 59 (03) : 229 - 230
  • [8] Visual hallucinations and macular degeneration: An example of the Charles Bonnet syndrome
    Nadarajah, J
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (01): : 63 - 65
  • [9] Complex visual hallucinations with retention of insight: four cases of Charles Bonnet syndrome
    Ostojic, Vesna Tepsic
    Gojkovic, Zagorka
    Zivic, Bratislav
    VOJNOSANITETSKI PREGLED, 2023, 80 (10) : 871 - 874
  • [10] Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome
    Bundeff, Andrew W.
    Woodis, C. Brock
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (06) : 777 - 784